Christine Berni Silverstein Sells 13,093 Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Christine Berni Silverstein sold 13,093 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $76,724.98. Following the sale, the director owned 120,479 shares in the company, valued at approximately $706,006.94. This trade represents a 9.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Abeona Therapeutics Stock Down 1.9%

NASDAQ:ABEO traded down $0.11 during midday trading on Friday, hitting $5.74. 774,254 shares of the company were exchanged, compared to its average volume of 701,588. The company has a fifty day simple moving average of $6.01 and a 200 day simple moving average of $5.57. Abeona Therapeutics Inc. has a fifty-two week low of $3.93 and a fifty-two week high of $7.32. The company has a current ratio of 4.90, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $293.64 million, a PE ratio of -4.52 and a beta of 1.51.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.11. As a group, equities analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $19.00 price objective on the stock. HC Wainwright raised their price objective on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Finally, Stifel Nicolaus reduced their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $19.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ABEO. Wellington Management Group LLP purchased a new position in Abeona Therapeutics during the 4th quarter worth $520,000. Trexquant Investment LP purchased a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $382,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after acquiring an additional 652,366 shares in the last quarter. Oxford Asset Management LLP purchased a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $118,000. Finally, Northern Trust Corp boosted its holdings in shares of Abeona Therapeutics by 6.6% in the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock valued at $1,030,000 after acquiring an additional 11,478 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.